IP Library Granted Patent US 7,655,463
Granted Patent B2
US 7,655,463 · App. 12/029,917 · Granted Feb 2, 2010

Methods of activating RET receptor tyrosine kinase using neurotrophic factors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,655,463
App. No.
12/029,917
Granted
Feb 2, 2010
Kind
B2
Abstract

The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.

Claims (16)

1. A method of activating a Rearranged During Transfection (RET) receptor tyrosine kinase, the method comprising contacting a cell expressing RET and Glial Cell Line-Derived Neurotrophic Factor Family Receptor Alpha-3 (GFRalpha3) with an amount of a dimerized protein effective to bind to a complex comprising RET and GFRalpha3 and induce dimerization and autophosphorylation of RET, thereby activating the RET receptor tyrosine kinase, wherein the dimerized protein is a homodimer consisting of two polypeptides each of which consists of an amino acid sequence selected from the group consisting of amino acids 37-140 of SEQ ID NO:9 (NBN 104), amino acids 39-140 of SEQ ID NO:9 (NBN 102), and amino acids 42-140 of SEQ ID NO:9 (NBN 99).

2. The method of claim 1 , wherein each of the polypeptides consists of amino acids 37-140 of SEQ ID NO:9 (NBN 104).

3. The method of claim 1 , wherein each of the polypeptides consists of amino acids 39-140 of SEQ ID NO:9 (NBN 102).

4. The method of claim 1 , wherein each of the polypeptides consists of amino acids 42-140 of SEQ ID NO:9 (NBN 99).

5. The method of claim 1 , wherein the cell is a nerve or neuronal cell.

6. The method of claim 2 , wherein the cell is a nerve or neuronal cell.

7. The method of claim 3 , wherein the cell is a nerve or neuronal cell.

8. The method of claim 4 , wherein the cell is a nerve or neuronal cell.

9. The method of claim 1 , wherein the cell is a human cell.

10. The method of claim 2 , wherein the cell is a human cell.

11. The method of claim 3 , wherein the cell is a human cell.

12. The method of claim 4 , wherein the cell is a human cell.

13. The method of claim 5 , wherein the cell is a human cell.

14. The method of claim 6 , wherein the cell is a human cell.

15. The method of claim 7 , wherein the cell is a human cell.

16. The method of claim 8 , wherein the cell is a human cell.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: GLORIANA THERAPEUTICS
To: SINFONIA BIOTHERAPEUTICS AB
Reel/Frame 062287/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2022
From: GLORIANA THERAPEUTICS, INC.
To: SINFONIA BIOTHERAPEUTICS AB
Reel/Frame 060711/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2019
From: GLORIANA THERAPEUTICS SARL
To: GLORIANA THERAPEUTICS, INC.
Reel/Frame 049005/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: BIOGEN MA INC.
To: GLORIANA THERAPEUTICS SARL
Reel/Frame 041887/0117 →
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2008
From: SAH, DINAH W.; ROSSOMANDO, ANTHONY
To: BIOGEN IDEC MA INC.
Reel/Frame 020577/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2008
From: JOHANSEN, TEIT E.
To: NSGENE A/S
Reel/Frame 020577/0546 →